SCHEMBL3179257

SCHEMBL3179257

CCOC(=O)CC(=O)c1ccccc1OCc1cccc(OC)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 5/20 0.52
HTR1A P08908 3/20 0.50
DRD2 P14416 2/20 0.50
LRRK2 Q5S007 1/20 0.49
ADRA1D P25100 1/20 0.47
ADRA1A P35348 1/20 0.47
ADRA1B P35368 1/20 0.47
MTNR1A P48039 3/20 0.47
MTNR1B P49286 2/20 0.47
MAPT P10636 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HTT P42858 2/20 0.46
KDM4E B2RXH2 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
GAA P10253 1/20 0.46
AKR1C3 P42330 1/20 0.46
NPSR1 Q6W5P4 2/20 0.45
POLB P06746 1/20 0.45
RECQL P46063 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2463767 0.87 ABCB1 (0.52) ABCB1HTR1ALRRK2ADRA1DADRA1A
SCHEMBL3178001 0.87 ABCB1 (0.52) ABCB1MAPTSMN1; SMN2HTTKDM4E
SCHEMBL377080 0.85 ABCB1 (0.61) ABCB1MAPTHTTNPC1GAA
SCHEMBL1388008 0.80 MRGPRX4 (0.59) ABCB1HTR1ADRD2LRRK2SMN1; SMN2
SCHEMBL3175398 0.80 ABCB1 (0.48) ABCB1MAPTKDM4ENPC1GAA
SCHEMBL954173 0.79 NPC1 (0.62) ABCB1MAPTSMN1; SMN2HTTKDM4E
SCHEMBL30218361 0.79 NPC1 (0.62) ABCB1MAPTSMN1; SMN2HTTKDM4E
SCHEMBL11339085 0.79 HCRTR1 (0.58) ABCB1MAPTSMN1; SMN2KDM4ENPC1
SCHEMBL8980573 0.78 LRRK2 (0.54) ABCB1HTR1ADRD2LRRK2ADRA1D
SCHEMBL1097702 0.77 MRGPRX4 (0.50) ABCB1HTR1ADRD2LRRK2MTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645772-B2 4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid; Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis WELLSTAT THERAPEUTICS CORPORATION (US) 2010-01-12 US claimed
US-20060035970-A1 Compounds for the treatment of metabolic disorders WELLSTAT THERAPEUTICS CORPORATION 2006-02-16 US claimed
EP-1556085-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Wellstat Therapeutics Corporation (US) 2005-07-27 EP claimed
WO-2004041165-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2004-05-21 WO claimed
US-7645772-B2 4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid; Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis WELLSTAT THERAPEUTICS CORPORATION (US) 2010-01-12 US disclosed
US-20060035970-A1 Compounds for the treatment of metabolic disorders WELLSTAT THERAPEUTICS CORPORATION 2006-02-16 US disclosed
EP-1556085-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Wellstat Therapeutics Corporation (US) 2005-07-27 EP disclosed
WO-2004041165-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2004-05-21 WO disclosed